Learn about Tacere Therapeutics
Tacere Therapeutics, Inc. (Tacere) is a wholly-owned subsidiary of Benitec Biopharma, the leader in DNA-based gene-silencing technology called ddRNAi.
Collaboration with Pfizer
Founded in 2006 and originally located in San Jose, California, USA, the team at Tacere created a hepatitis C treatment called TT-034, based on proprietary DNA constructs and Benitec’s ddRNAi technology. Between 2008 and 2011 Tacere collaborated with Pfizer Inc.(Pfizer) to develop and commercialize TT-034. By 2011, Pfizer had progressed the TT-034 program significantly, culminating in completion of Good Laboratory Practice (GLP) toxicology studies for the drug.
However, after a corporate restructure, Pfizer closed the research facility where the TT-034 program was based, and all rights reverted to Tacere. By 2012, the draft reports from the toxicology studies had been released which showed favourable results.
Acquisition by Benitec
In October 2012, the circle was completed when Benitec acquired Tacere and its programs, including TT-034 for Hepatitis C and its treatment for Age-Related Macular Degeneration. TT-034 entered Phase I/IIa clinical trials in early 2014, with dosing of the first patient in May. See more details in our TT-034 pipeline.
In July 2014, the team formerly from Tacere, including Dr David Suhy, Senior VP of Research & Development and creator of TT-034, moved to Benitec's new laboratory in the Bay Area of San Francisco. This facility has been named the Bremner Laboratory to honour the Dr Christopher Bremner, a seminal and key long term investor in Benitec.